Share This Page
Drug Price Trends for VICTOZA
✉ Email this page to a colleague

Average Pharmacy Cost for VICTOZA
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
VICTOZA 2-PAK 18 MG/3 ML PEN | 00169-4060-12 | 87.42700 | ML | 2025-01-22 |
VICTOZA 3-PAK 18 MG/3 ML PEN | 00169-4060-13 | 87.45675 | ML | 2025-01-22 |
VICTOZA 3-PAK 18 MG/3 ML PEN | 00169-4060-13 | 87.44060 | ML | 2024-12-18 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Victoza (Liraglutide)
Introduction to Victoza
Victoza, also known by its generic name liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and, under the brand name Saxenda, for weight loss. It is administered as a subcutaneous injection and has been a significant player in the diabetes and obesity treatment markets since its approval in 2010.
Current Market Scenario
Launch of Generic Victoza
In a significant development, Teva Pharmaceuticals has launched the first generic version of Victoza in the U.S., marking a major milestone in improving access to GLP-1 medications. This launch comes at a time when many patients with diabetes are facing shortages of other GLP-1 and incretin medications like Ozempic and Mounjaro[1].
Pricing of Generic Victoza
The generic version of Victoza is priced at $469.60 for a two-pack and $704.40 for a three-pack, representing a 16% to 17% reduction compared to the brand-name version, which typically costs around $560 for a two-pack and $850 for a three-pack[1].
Competition and Future Launches
In addition to Teva’s generic, two other companies, Sandoz and Viatris, are developing their own generic versions of Victoza. These could be launched as soon as December 2024, further increasing competition and potentially driving prices down[1].
Market Size and Growth Projections
Liraglutide Market Size
The liraglutide market, which includes both Victoza and Saxenda, is estimated to be worth $3.40 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.16% to reach $4 billion by 2029. North America is the largest and fastest-growing market for liraglutide[4].
Global GLP-1 Market
The global GLP-1 market is poised for significant growth, expected to reach $471.1 billion by 2032, with a CAGR of 33.2%. This growth is driven by increasing demand for GLP-1 medications in treating type 2 diabetes and obesity, particularly in North America[3].
Price Pressures and Market Dynamics
Impact of Generic Entries
The entry of generic versions of Victoza is expected to increase price competition in the GLP-1 market. As more generics become available, prices are likely to decline further, making these medications more accessible to a wider patient population[1].
Regulatory and Policy Influences
The Inflation Reduction Act, which includes provisions for Medicare price negotiations, is expected to add further pressure on GLP-1 pricing starting in 2027. This could lead to a 10% to 15% decline in prices as companies strive to maintain market share and secure insurance coverage[3].
Patient Access and Affordability
Cost Savings with Generics
The introduction of generic Victoza is anticipated to significantly improve patient access to GLP-1 medications. The reduced prices will help alleviate the financial burden on patients, especially those who are underinsured or uninsured. For instance, the generic version is already priced lower than the brand-name version, and additional generic entries are expected to drive prices down further[1].
Comparison with Other GLP-1 Medications
While Victoza offers modest A1C lowering and weight loss compared to newer GLP-1s like Ozempic, its generic availability makes it a more affordable option. For example, in the SUSTAIN 10 study, Victoza reduced A1C by 1% and led to a weight loss of about 4 pounds, whereas Ozempic reduced A1C by 1.7% and led to a weight loss of about 13 pounds[1].
Industry Segmentation and Major Players
Market Segmentation
The liraglutide market is segmented by brand (Victoza and Saxenda) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). North America is the largest market for both Victoza and Saxenda[4].
Major Players
Novo Nordisk, the original manufacturer of Victoza, has dominated the GLP-1 market for several years. However, with the entry of generics, other players like Teva, Sandoz, and Viatris are gaining traction. The competitive landscape is expected to evolve rapidly, with new entrants and generic versions challenging the market dominance of established brands[1][3].
Future Outlook
New Market Entrants and Innovations
By 2029, it is predicted that 16 new weight-loss drugs, including GLP-1s, could enter the market. This influx of new medications will further complicate market dynamics, potentially leading to lower prices and increased competition among manufacturers[3].
Regulatory and Policy Changes
The Inflation Reduction Act and other regulatory changes are expected to influence pricing and market access. Forced Medicare price negotiations for drugs like Wegovy starting in 2027 will add to the pricing pressure on GLP-1 medications[3].
Key Takeaways
- Generic Availability: The launch of generic Victoza marks a significant step in improving access to GLP-1 medications, especially amid shortages of other GLP-1s.
- Price Reduction: Generic versions are priced lower than the brand-name version, with further price declines expected as more generics enter the market.
- Market Growth: The global GLP-1 market is projected to grow substantially, driven by increasing demand for type 2 diabetes and obesity treatments.
- Competition: The entry of new generics and regulatory changes will increase competition, leading to potential price reductions and improved patient access.
- Regulatory Impact: Policies like the Inflation Reduction Act will play a crucial role in shaping the pricing and accessibility of GLP-1 medications.
FAQs
Q: What is the current price of generic Victoza?
The generic version of Victoza is priced at $469.60 for a two-pack and $704.40 for a three-pack[1].
Q: When can we expect more generic versions of Victoza to be available?
Additional generic versions of Victoza are expected to launch as soon as December 2024[1].
Q: How does the efficacy of generic Victoza compare to newer GLP-1s?
Generic Victoza offers modest A1C lowering and weight loss compared to newer GLP-1s like Ozempic. For example, Victoza reduced A1C by 1% and led to a weight loss of about 4 pounds, whereas Ozempic reduced A1C by 1.7% and led to a weight loss of about 13 pounds[1].
Q: What is the projected growth of the global GLP-1 market?
The global GLP-1 market is expected to reach $471.1 billion by 2032, growing at a CAGR of 33.2%[3].
Q: How will regulatory changes impact the pricing of GLP-1 medications?
Regulatory changes, such as the Inflation Reduction Act, are expected to increase pricing pressure on GLP-1 medications, leading to potential price declines starting in 2027[3].
Sources
- diaTribe.org: "Generic Victoza Now Available in the U.S."
- SingleCare: "Victoza Coupons & Prices"
- PharmExec: "Obesity Drug Market Estimated to be Worth $200 Billion by 2031"
- Mordor Intelligence: "Liraglutide Market Size & Share Analysis - Industry Research Report"
- Drugs.com: "Victoza Prices, Coupons, Copay Cards & Patient Assistance"
More… ↓